232 related articles for article (PubMed ID: 23316863)
1. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa.
Al-Horani RA; Ponnusamy P; Mehta AY; Gailani D; Desai UR
J Med Chem; 2013 Feb; 56(3):867-78. PubMed ID: 23316863
[TBL] [Abstract][Full Text] [Related]
2. Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides.
Al-Horani RA; Desai UR
J Med Chem; 2014 Jun; 57(11):4805-18. PubMed ID: 24844380
[TBL] [Abstract][Full Text] [Related]
3. Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.
Al-Horani RA; Gailani D; Desai UR
Thromb Res; 2015 Aug; 136(2):379-87. PubMed ID: 25935648
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia.
Kar S; Mottamal M; Al-Horani RA
ChemistryOpen; 2020 Nov; 9(11):1161-1172. PubMed ID: 33204588
[TBL] [Abstract][Full Text] [Related]
5. A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.
Al-Horani RA; Abdelfadiel EI; Afosah DK; Morla S; Sistla JC; Mohammed B; Martin EJ; Sakagami M; Brophy DF; Desai UR
J Thromb Haemost; 2019 Dec; 17(12):2110-2122. PubMed ID: 31397071
[TBL] [Abstract][Full Text] [Related]
6. Allosteric inhibition of human factor XIa: discovery of monosulfated benzofurans as a class of promising inhibitors.
Argade MD; Mehta AY; Sarkar A; Desai UR
J Med Chem; 2014 Apr; 57(8):3559-69. PubMed ID: 24666186
[TBL] [Abstract][Full Text] [Related]
7. Studies on fragment-based design of allosteric inhibitors of human factor XIa.
Boothello RS; Sankaranarayanan NV; Afosah DK; Karuturi R; Al-Horani RA; Desai UR
Bioorg Med Chem; 2020 Dec; 28(23):115762. PubMed ID: 32992249
[TBL] [Abstract][Full Text] [Related]
8. Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies.
Al-Horani RA; Parsaeian E; Mohammad M; Mottamal M
Chem Biol Drug Des; 2022 Jul; 100(1):64-79. PubMed ID: 35377529
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.
Corte JR; Fang T; Osuna H; Pinto DJ; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Decicco CP; Wexler RR; Quan ML
J Med Chem; 2017 Feb; 60(3):1060-1075. PubMed ID: 28085275
[TBL] [Abstract][Full Text] [Related]
10. Macrocyclic factor XIa inhibitors.
Wang C; Corte JR; Rossi KA; Bozarth JM; Wu Y; Sheriff S; Myers JE; Luettgen JM; Seiffert DA; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2017 Sep; 27(17):4056-4060. PubMed ID: 28780160
[TBL] [Abstract][Full Text] [Related]
11. Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design.
Fjellström O; Akkaya S; Beisel HG; Eriksson PO; Erixon K; Gustafsson D; Jurva U; Kang D; Karis D; Knecht W; Nerme V; Nilsson I; Olsson T; Redzic A; Roth R; Sandmark J; Tigerström A; Öster L
PLoS One; 2015; 10(1):e0113705. PubMed ID: 25629509
[TBL] [Abstract][Full Text] [Related]
12. SERPIN regulation of factor XIa. The novel observation that protease nexin 1 in the presence of heparin is a more potent inhibitor of factor XIa than C1 inhibitor.
Knauer DJ; Majumdar D; Fong PC; Knauer MF
J Biol Chem; 2000 Dec; 275(48):37340-6. PubMed ID: 10973954
[TBL] [Abstract][Full Text] [Related]
13. Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site.
Karuturi R; Al-Horani RA; Mehta SC; Gailani D; Desai UR
J Med Chem; 2013 Mar; 56(6):2415-28. PubMed ID: 23451707
[TBL] [Abstract][Full Text] [Related]
14. The role of factor XIa (FXIa) catalytic domain exosite residues in substrate catalysis and inhibition by the Kunitz protease inhibitor domain of protease nexin 2.
Su YC; Miller TN; Navaneetham D; Schoonmaker RT; Sinha D; Walsh PN
J Biol Chem; 2011 Sep; 286(36):31904-14. PubMed ID: 21778227
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
16. Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.
Hu Z; Wang C; Han W; Rossi KA; Bozarth JM; Wu Y; Sheriff S; Myers JE; Luettgen JM; Seiffert DA; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2018 Apr; 28(6):987-992. PubMed ID: 29501396
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor.
Yang L; Sun MF; Gailani D; Rezaie AR
Biochemistry; 2009 Feb; 48(7):1517-24. PubMed ID: 19178150
[TBL] [Abstract][Full Text] [Related]
18. Factor XIa inhibitors: A review of the patent literature.
Al-Horani RA; Desai UR
Expert Opin Ther Pat; 2016; 26(3):323-45. PubMed ID: 26881476
[TBL] [Abstract][Full Text] [Related]
19. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI.
Schaefer M; Buchmueller A; Dittmer F; Straßburger J; Wilmen A
J Mol Biol; 2019 Dec; 431(24):4817-4833. PubMed ID: 31655039
[TBL] [Abstract][Full Text] [Related]
20. Asymmetric Synthesis of Silanediol Inhibitors for the Serine Protease Coagulation Cascade Enzyme FXIa.
Duong HQ; Sieburth SM
J Org Chem; 2018 May; 83(10):5398-5409. PubMed ID: 29667397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
